<DOC>
	<DOC>NCT02432911</DOC>
	<brief_summary>This study focus on the comparison of CAG regimen to the low dose cytarabine therapy in elderly AML patients who are unfit or unwilling to receive intensive chemotherapy.</brief_summary>
	<brief_title>Treatment of Elderly Chinese Acute Myeloid Leukemia Patients Aged 65 to 75 Years Old</brief_title>
	<detailed_description>Low dose cytarabine remains to be the choice of standard for elderly AML patients who are unfit or unwilling to receive intensive treatment. CAG regimen, which is a combination of aclacinomycin，low dose cytarabine±G-CSF is used often in elderly AML patients in China. It is proved effective and safety in some pilot studies，while there is no prospective，randomized study yet.</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia, Myeloid</mesh_term>
	<mesh_term>Leukemia, Myeloid, Acute</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Aclacinomycins</mesh_term>
	<mesh_term>Aclarubicin</mesh_term>
	<criteria>Acute myeloid leukemia except APL ECOG PS：03 Unfit or unwilling to receive intensive therapy The one who has already received induction therapy no matter what the outcome is. Active cancer patients who are needed to receive treatment; Serious uncontrolled infectious diseases(eg.tuberculosis or invasive pulmonary aspergillosis）； Active heart disease</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>